Search in:

Advanced search

International Journal of Chronic Obstructive Pulmonary Disease Volume 11, 2016 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

Craig LaForce1 North Carolina Clinical Research, Raleigh, NC, USACorrespondence[email protected]

Gregory Feldman2 South Carolina Pharmaceutical Research, Spartanburg, SC, USA

Selwyn Spangenthal3 American Health Research, Charlotte, NC, USA

Joerg H Eckert4 Novartis Pharma AG, Basel, Switzerland

Michelle Henley5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Francesco Patalano4 Novartis Pharma AG, Basel, Switzerland

Peter D’Andrea5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

show all

Pages 1233-1243 | Published online: 08 Jun 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

FerkolTSchraufnagelDThe global burden of respiratory diseaseAnn Am Thorac Soc201411340440624673696
PubMedGoogle Scholar
National Heart, Lung and Blood InstituteMorbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases2012 Available from: http://www.nhlbi.nih.gov/research/reports/2012-mortality-chart-bookAccessed 22 July, 2015
Google Scholar
RiesALImpact of chronic obstructive pulmonary disease on quality of life: the role of dyspneaAm J Med200611910 Suppl 1122016996895
PubMed Web of Science ®Google Scholar
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease2016 Available from: http://www.goldcopd.orgAccessed February 2, 2016
Google Scholar
Seebri Breezhaler^® (glycopyrronium bromide) [summary of product characteristics]Nuremberg, GermanyNovartis Pharma GmbH2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdfAccessed February 2, 2016
Google Scholar
DomingoCUltra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landedArch Bronconeumol201349413113423415574
PubMed Web of Science ®Google Scholar
D’UrzoAKerwinEOverendTD’AndreaPChenHGoyalPOnce daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studiesCurr Med Res Opin201430349350824156566
PubMed Web of Science ®Google Scholar
ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
PubMed Web of Science ®Google Scholar
KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
PubMed Web of Science ®Google Scholar
ArievichHOverendTRenardDA novel model-based approach for dose determination of glycopyrronium bromide in COPDBMC Pulm Med2012127423217058
PubMed Web of Science ®Google Scholar
FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler^® for patients with chronic obstructive pulmonary disease10292015 Available from: http://www.pharma.us.novartis.com/info/newsroom/news-description.jsp?id=137236Accessed May 2, 2016
Google Scholar
JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
PubMed Web of Science ®Google Scholar
WangCSunTHuangYEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyInt J Chron Obstruct Pulmon Dis201510576825609940
PubMed Web of Science ®Google Scholar
KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J201137226427221115606
PubMed Web of Science ®Google Scholar
RocheNChavannesNHMiravitllesMCOPD symptoms in the morning: impact, evaluation and managementRespir Res20131411224143997
PubMed Web of Science ®Google Scholar
BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
PubMed Web of Science ®Google Scholar
DecramerMCooperCBTreatment of COPD: the sooner the better?Thorax201065983784120805184
PubMed Web of Science ®Google Scholar
RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig20133312893904
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date